Accueil>>Peptides>>Atrial natriuretic factor (1-28) (rat)

Atrial natriuretic factor (1-28) (rat)

Catalog No.GC11314

Le facteur natriurétique auriculaire (1-28) (rat) est une forme circulante majeure d'ANP chez le rat, inhibe puissamment la sécrétion d'endothéline-1 stimulée par l'angiotensine II (Ang II) d'une manière dépendante de la concentration.

Products are for research use only. Not for human use. We do not sell to patients.

Atrial natriuretic factor (1-28) (rat) Chemical Structure

Cas No.: 88898-17-3

Taille Prix Stock Qté
1mg
246,00 $US
Ship Within 7 Days

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Atrial Natriuretic Peptide (ANP) (1-28), rat is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated endothelin-1 secretion in a concentration-dependent manner.

Rat ANP (1-28) and rat BNP-45, which are the respective major circulating forms of ANP and BNP in rats, potently inhibited Ang II-stimulated endothelin-1 secretion in a concentration-dependent manner. Rat ANP (5-25) is less effective that Rat ANP(1-28) with respect to inhibiting immunoreactive (ir)-endothelin-1 secretion and increasing cellular cyclic GMP. Rat ANP (1-28) inhibits the secretion of ir-endothelin-1 in a concentration-dependent manner between 0.01 and 1 μM[1].

References:
[1]. Kohno M, et al. Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells. Kidney Int. 1992 Oct;42(4):860-6.

Avis

Review for Atrial natriuretic factor (1-28) (rat)

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Atrial natriuretic factor (1-28) (rat)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.